NEWRON PHARMACEUTICALS SPA (NP5.DE) Fundamental Analysis & Valuation

FRA:NP5 • IT0004147952

Current stock price

15.55 EUR
-1.05 (-6.33%)
Last:

This NP5.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. NP5.DE Profitability Analysis

1.1 Basic Checks

  • NP5 had negative earnings in the past year.
  • NP5 had a positive operating cash flow in the past year.
  • In the past 5 years NP5 reported 4 times negative net income.
  • In the past 5 years NP5 always reported negative operating cash flow.
NP5.DE Yearly Net Income VS EBIT VS OCF VS FCFNP5.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

  • NP5 has a better Return On Assets (41.25%) than 100.00% of its industry peers.
  • NP5's Return On Equity of 1600.95% is amongst the best of the industry. NP5 outperforms 100.00% of its industry peers.
  • NP5 has a better Return On Invested Capital (122.31%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 41.25%
ROE 1600.95%
ROIC 122.31%
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NP5.DE Yearly ROA, ROE, ROICNP5.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • NP5 has a Profit Margin of 42.30%. This is amongst the best in the industry. NP5 outperforms 100.00% of its industry peers.
  • NP5's Operating Margin of 58.78% is amongst the best of the industry. NP5 outperforms 100.00% of its industry peers.
  • Looking at the Gross Margin, with a value of 98.17%, NP5 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • NP5's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 58.78%
PM (TTM) 42.3%
GM 98.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
NP5.DE Yearly Profit, Operating, Gross MarginsNP5.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NP5.DE Health Analysis

2.1 Basic Checks

  • NP5 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • NP5 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NP5.DE Yearly Shares OutstandingNP5.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NP5.DE Yearly Total Debt VS Total AssetsNP5.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • NP5 has an Altman-Z score of 6.76. This indicates that NP5 is financially healthy and has little risk of bankruptcy at the moment.
  • NP5's Altman-Z score of 6.76 is amongst the best of the industry. NP5 outperforms 90.20% of its industry peers.
  • The Debt to FCF ratio of NP5 is 2.14, which is a good value as it means it would take NP5, 2.14 years of fcf income to pay off all of its debts.
  • NP5 has a better Debt to FCF ratio (2.14) than 78.43% of its industry peers.
  • NP5 has a Debt/Equity ratio of 11.80. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of NP5 (11.80) is worse than 84.31% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for NP5, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 11.8
Debt/FCF 2.14
Altman-Z 6.76
ROIC/WACC16.46
WACC7.43%
NP5.DE Yearly LT Debt VS Equity VS FCFNP5.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • NP5 has a Current Ratio of 1.51. This is a normal value and indicates that NP5 is financially healthy and should not expect problems in meeting its short term obligations.
  • NP5 has a Current ratio of 1.51. This is in the better half of the industry: NP5 outperforms 60.78% of its industry peers.
  • NP5 has a Quick Ratio of 1.51. This is a normal value and indicates that NP5 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.51, NP5 is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
NP5.DE Yearly Current Assets VS Current LiabilitesNP5.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NP5.DE Growth Analysis

3.1 Past

  • NP5 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -177.65%.
EPS 1Y (TTM)-177.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-148.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-84.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 55.31% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, NP5 will show a very strong growth in Revenue. The Revenue will grow by 59.71% on average per year.
EPS Next Y-74.33%
EPS Next 2Y17.88%
EPS Next 3Y109.72%
EPS Next 5Y55.31%
Revenue Next Year-22.71%
Revenue Next 2Y54.32%
Revenue Next 3Y-19.66%
Revenue Next 5Y59.71%

3.3 Evolution

NP5.DE Yearly Revenue VS EstimatesNP5.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
NP5.DE Yearly EPS VS EstimatesNP5.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. NP5.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NP5. In the last year negative earnings were reported.
  • Also next year NP5 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NP5.DE Price Earnings VS Forward Price EarningsNP5.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NP5 indicates a somewhat cheap valuation: NP5 is cheaper than 78.43% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, NP5 is valued cheaply inside the industry as 80.39% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.16
EV/EBITDA 8.92
NP5.DE Per share dataNP5.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • NP5 has a very decent profitability rating, which may justify a higher PE ratio.
  • NP5's earnings are expected to grow with 109.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.88%
EPS Next 3Y109.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NP5.DE Dividend Analysis

5.1 Amount

  • No dividends for NP5!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NP5.DE Fundamentals: All Metrics, Ratios and Statistics

NEWRON PHARMACEUTICALS SPA

FRA:NP5 (4/7/2026, 7:00:00 PM)

15.55

-1.05 (-6.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-24
Earnings (Next)N/A
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners10.54%
Ins Owner ChangeN/A
Market Cap322.82M
Revenue(TTM)N/A
Net Income(TTM)25.33M
Analysts82.22
Price Target53.22 (242.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)164.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.24%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.23%
Revenue NY rev (3m)-3.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.39
P/FCF 13.16
P/OCF 13.14
P/B 204.06
P/tB 204.19
EV/EBITDA 8.92
EPS(TTM)-0.66
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)1.18
FCFY7.6%
OCF(TTM)1.18
OCFY7.61%
SpS2.88
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 41.25%
ROE 1600.95%
ROCE 165.16%
ROIC 122.31%
ROICexc N/A
ROICexgc N/A
OM 58.78%
PM (TTM) 42.3%
GM 98.17%
FCFM 40.96%
ROA(3y)-28.32%
ROA(5y)-31.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y4.26%
F-Score6
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 11.8
Debt/FCF 2.14
Debt/EBITDA 0.53
Cap/Depr 20.99%
Cap/Sales 0.06%
Interest Coverage 33.98
Cash Conversion 69.43%
Profit Quality 96.85%
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z 6.76
F-Score6
WACC7.43%
ROIC/WACC16.46
Cap/Depr(3y)7.05%
Cap/Depr(5y)9.34%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-177.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-148.24%
EPS Next Y-74.33%
EPS Next 2Y17.88%
EPS Next 3Y109.72%
EPS Next 5Y55.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-84.94%
Revenue Next Year-22.71%
Revenue Next 2Y54.32%
Revenue Next 3Y-19.66%
Revenue Next 5Y59.71%
EBIT growth 1Y334.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-151.15%
EBIT Next 3Y-30.83%
EBIT Next 5Y30.92%
FCF growth 1Y321.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.02%
OCF growth 3YN/A
OCF growth 5YN/A

NEWRON PHARMACEUTICALS SPA / NP5.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEWRON PHARMACEUTICALS SPA?

ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE.


What is the valuation status of NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?

ChartMill assigns a valuation rating of 4 / 10 to NEWRON PHARMACEUTICALS SPA (NP5.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for NEWRON PHARMACEUTICALS SPA?

NEWRON PHARMACEUTICALS SPA (NP5.DE) has a profitability rating of 6 / 10.


What is the expected EPS growth for NEWRON PHARMACEUTICALS SPA (NP5.DE) stock?

The Earnings per Share (EPS) of NEWRON PHARMACEUTICALS SPA (NP5.DE) is expected to decline by -74.33% in the next year.